This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bio-Reference Laboratories, Inc. Announces Strong Growth Resulting In Record First Quarter Revenue And Earnings

Stocks in this article: BRLI

Dr. Grodman concluded, "We re-affirm our guidance for our current fiscal year as announced in our Q4FY12 earnings call. We remain focused on being the technology leader, the marketing leader as well as the service leader in a service-dominated industry. We believe we grow because we are able to identify the needs of the clinical diagnostic market and provide solutions to the needs of the healthcare providers. We are committed to the disruptive technology and reporting advancements that have been the hallmark of our sustained growth and remain dedicated to continuing that model as we move forward."

The Company's Q1FY13 earnings conference call has been scheduled to take place this morning, February 28, 2013 at 10:30 a.m. Eastern Standard Time. The live audio Web cast will be available at the Company's corporate Web site, and through . To listen to the call please go to either Web site ten minutes before the conference call is scheduled to begin. You will need to register as well as download and install any necessary audio software. The Web cast will be archived, on both Web sites, for 30 days following the call.

Bio-Reference Laboratories, Inc.
Statements of Operations
(Dollars in Thousands Except Share and Per Share Data)
Three Months Ended
January 31,
    (As Adjusted (As Previously
    for Topic 954) Reported)
  2013 2012 2012
Net Revenues $161,256 $138,793 $149,919
Cost of Sales 90,334 78,676 78,676
Gross Profit on Revenues 70,922 60,117 71,243
General and Administrative 55,163 46,835 57,961
Operating Income 15,759 13,282 13,282
Other Expense, Net 386 316 316
Income Before Taxes 15,373 12,966 12,966
Taxes 6,708 5,601 5,601
Net Income 8,665 7,365 7,365
Income Per Share $0.31 $0.26 $0.26
Number of Shares 27,716,336 27,887,717 27,887,717
Income Per Share (Diluted) $0.31 $0.26 $0.26
Number of Shares (Diluted) 27,912,327 28,041,022 28,041,022
Bio-Reference Laboratories, Inc.
Balance Sheets
(Dollars in Thousands)
  January 31, October 31,
  2013 2012
Cash & Cash Equivalents $26,316 $25,143
Accounts Receivable (Net) 161,289 153,247
Plant, Property & Equipment (Net) 51,569 50,440
Intangible Assets (Net) 36,235 29,731
Other Assets 55,236 54,264
Total $330,645 $312,825
Accounts Payable $42,656 $41,288
Revolving Note 6,684  --
Long-Term Debt 17,500 18,047
Other Liabilities 27,595 26,243
Shareholder's Equity 236,210 227,247
Total $330,645 $312,825

About Bio-Reference Laboratories, Inc .

BRLI is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. We believe that we are the fourth largest full-service laboratory in the United States and the largest independent regional laboratory in the Northeastern market. BRLI offers a comprehensive list of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. BRLI primarily focuses on esoteric testing, molecular diagnostics, anatomical pathology, women's health and correctional health care. 

3 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs